PALO ALTO, Calif.--(BUSINESS WIRE)--The U.S. therapeutic monoclonal antibodies market is poised for a quantum leap with the launch of a multitude of new products and vigorous expansion of therapeutic indications of existing products. A combination of these factors, along with high demand and lack of generic competition, expects to create exciting new possibilities and ensure continued market growth.
